Antiarrhythmic drugs in patients with CAD, observational studies, GLP-1 agonists, and the subcutaneous ICD are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. AAD in Patients with CAD
- The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease
https://doi.org/10.1016/j.jacep.2022.12.021
- Three Questions for Evidence-Based Cardiac Electrophysiology
https://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381
- The Cardiac Arrhythmia Suppression Trial (CAST) https://www.nejm.org/doi/full/10.1056/nejm198908103210608
II. GLP-1 Agonists
Tirzepatide Powers Weight Loss in Two More Pivotal Trials https://www.medscape.com/viewarticle/994889
Semaglutide Use Surges in US Adults With Type 2 Diabetes https://www.medscape.com/viewarticle/994873
- Tirzepatide Once Weekly for the Treatment of Obesity
https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
https://doi.org/10.1016/S0140-6736(23)01200-X
III. S-ICD
S-ICD Shows Virtues, Limits in 'Real World' Postmarket Study https://www.medscape.com/viewarticle/994851
- Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System https://doi.org/10.1016/j.jacc.2023.05.034
- Subcutaneous or Transvenous Defibrillator Therapy https://www.nejm.org/doi/full/10.1056/NEJMoa1915932
- Letter to the Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
